What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Keros Therapeutics, Inc. (KROS) - Keros Therapeutics, Inc. currently holds a Momentum Style Score of B and a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance [2][3] - The stock has shown significant price increases, with shares up 24.08% over the past week, while the Zacks Medical - Biomedical and Genetics industry has declined by 1.16% during the same period [5] - Over the past quarter, KROS shares have increased by 35.22%, and over the last year, they have gained 17.69%, outperforming the S&P 500, which moved 5.09% and 14.7% respectively [6] Trading Volume - KROS has an average 20-day trading volume of 1,106,472 shares, which is considered a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 7 earnings estimates for KROS have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.20 to $2.25 [9] - For the next fiscal year, 7 estimates have also moved upwards without any downward revisions, indicating positive earnings momentum [9] Conclusion - Given the strong performance metrics and positive earnings outlook, Keros Therapeutics, Inc. is positioned as a promising investment opportunity with a Momentum Score of B and a Zacks Rank of 1 (Strong Buy) [11]